Last reviewed · How we verify

NCT06631495

All-cause and Diseases-specific Mortality of High-risk HPV Infection

Not yet recruiting Last updated 8 October 2024
What this trial tests

trial testing Observation in HPV Infection in 100,000 participants. Not yet recruiting.

Timeline
1 October 2024
Primary endpoint
1 October 2026
1 October 2027

Quick facts

Lead sponsorPeking Union Medical College Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment100,000
Start date1 October 2024
Primary completion1 October 2026
Estimated completion1 October 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, female only, with HPV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The corresponding prevention strategies and treatment routes of HPV infection can be provided through investigating causes of death due to HPV infection and specialized diseases.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Observation

Trials testing the same drug.

Other recruiting trials for HPV Infection

Currently open trials in the same condition.

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06631495.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing